Physician profile
Michael Conners
NPI 1497772958
$2,903.33
in general payments reported to CMS, 2019-2025
22 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $47.02 · 2021: $15.68 · 2022: $393 · 2023: $645 · 2024: $911 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $661.47 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $332.40 | 2023-2025 | Durysta, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $263.66 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $260.07 | 2019-2025 | Clareon, Tryptyr, Argos |
| Bausch & Lomb Americas INC. | $215.41 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $200.03 | 2019-2025 | Cequa |
| Dompe US, INC. | $136.32 | 2022-2025 | Oxervate |
| Rxsight INC | $133.17 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $117.24 | 2024-2025 | Vevye |
| New World Medical,INC. | $103.75 | 2022 | |
| Amgen INC. | $85.64 | 2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $84.71 | 2024 | Purified Cortrophin Gel |
| Allergan, INC. | $81.40 | 2019-2022 | |
| Biotissue Holdings INC. | $65.08 | 2019-2024 | |
| Ocular Therapeutix, INC. | $35.56 | 2023 | Dextenza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $26.86 | 2025 | Syfovre |
| Shire North American Group INC | $24.48 | 2019 | |
| Sight Sciences, INC. | $17.46 | 2022 | |
| Carl Zeiss Meditec Cataract Technology INC. | $16.97 | 2019 | |
| Ivantis, INC | $15.68 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.95 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Conners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.